Nevertheless, our findings suggest that prospective evaluation of the BRAF mutation status is equally important in Chinese patients with colon cancer, even though its mutation frequency (4-7%) is lower than Western patients and no effective therapy available. This evidence concerns the gene BRAF and malignant colon neoplasm.